SCHEDULE: Mirabella Financial Services Reports 7.69% Stake in MAXCYTE

Mirabella Financial Services LLP has reported a 7.69% beneficial ownership stake in MAXCYTE, INC. common stock as of September 30, 2025.

Summary

• Mirabella Financial Services LLP, a UK-based investment adviser, has filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of 8,200,000 shares of MAXCYTE, INC. common stock.
• This represents 7.69% of MAXCYTE, INC.'s outstanding common stock.
• Mirabella Financial Services LLP holds sole voting and sole dispositive power over all 8,200,000 shares.
• The shares are reported on behalf of Blue Riband Fund LP, for which Mirabella Financial Services LLP acts as the Investment Manager.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of MAXCYTE, INC.

Sentiment

Score: 6

Explanation: The filing indicates a significant, passive institutional investment, which can be viewed positively as a vote of confidence. However, it is a standard regulatory disclosure and does not contain new operational or financial performance information from the issuer.

Future Outlook

NA

Industry Context

This filing reflects a significant passive investment by an institutional investor in MAXCYTE, INC., a company operating in the biotechnology or life sciences sector. Such filings are common for investment advisers managing funds and indicate a belief in the long-term value of the company's stock, without an intent to influence management or control.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder may provide some confidence in the stock's valuation and liquidity.

Key Dates

Keywords

MAXCYTE, Mirabella Financial Services, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, Equity Stake, Blue Riband Fund